Thyroid transcription factor-1 expression in colorectal adenocarcinomas.

Dettmer, Matthias; Kim, Tae Eun; Jung, Chan Kwon; Jung, Eun Sun; Lee, Kyo Young; Kang, Chang Suk (2011). Thyroid transcription factor-1 expression in colorectal adenocarcinomas. Pathology, research and practice, 207(11), pp. 686-690. Elsevier 10.1016/j.prp.2011.08.009

[img] Text
1-s2.0-S0344033811002147-main.pdf - Published Version
Restricted to registered users only
Available under License Publisher holds Copyright.

Download (1MB) | Request a copy

Although thyroid transcription factor-1 (TTF-1) immunoreactivity is considered as a specific marker of lung and thyroid neoplasms, it may be positive in a proportion of extrapulmonary adenocarcinomas. This study examined the expression of TTF-1 in 555 colorectal adenocarcinomas using three commercial monoclonal antibodies: clone SPT24 (Novocastra) and 8G7G3/1 (Dako and Cell Marque), and compared the TTF-1 staining with other immunohistochemical markers, cytokeratin (CK) 7, CK 20, caudal-type homeobox transcription factor 2 (CDX2), and MUC2. The clinicopathological prognostic factors were compared with the TTF-1 expression status. Nuclear TTF-1 staining was detected in 24 cases (4.3%) with the SPT24 antibody and 18 cases (3.2%) with the 8G7G3/1 antibody. All cases positive for 8G7G3/1 were also positive for SPT24. CDX2 was expressed constantly in all 24 TTF-1-positive colorectal cancers, whereas CK7, CK20, and MUC2 were detected in 2 (8.3%), 23 (95.8%), and 8 (33.3%) cases, respectively. There was no correlation between TTF-1 expression and clinicopathological significance. To avoid potential pitfalls, TTF-1 should be interpreted in conjunction with the clinical setting, histological features, and the results of other markers, such as CK7, CK20, and CDX2. MUC2 can be used as supplementary information to confirm difficult cases.

Item Type:

Journal Article (Original Article)

Division/Institute:

04 Faculty of Medicine > Service Sector > Institute of Pathology
04 Faculty of Medicine > Service Sector > Institute of Pathology > Tumour Pathology

UniBE Contributor:

Dettmer, Matthias

Subjects:

500 Science > 570 Life sciences; biology
600 Technology > 610 Medicine & health

ISSN:

0344-0338

Publisher:

Elsevier

Language:

English

Submitter:

Matthias Dettmer

Date Deposited:

04 Dec 2019 11:07

Last Modified:

04 Dec 2019 11:07

Publisher DOI:

10.1016/j.prp.2011.08.009

PubMed ID:

22019009

BORIS DOI:

10.7892/boris.136131

URI:

https://boris.unibe.ch/id/eprint/136131

Actions (login required)

Edit item Edit item
Provide Feedback